Understanding triclabendazole resistance
Brennan, GP
Fairweather, I
Trudgett, A
Hoey, E
McCoy
McConville, M
Meaney, M
Robinson, M
McFerran, N
Ryan, L
Lanusse, C
Mottier, L
Alvarez, L
Solana, H
Virkel, G
Brophy, PM
McFerran, N
Ryan, L
Lanusse, C
Mottier, L
Alvarez, L
Solana, H
Virkel, G
Brophy, PM
- Publication Type:
- Journal Article
- Citation:
- Experimental and Molecular Pathology, 2007, 82 (2), pp. 104 - 109
- Issue Date:
- 2007-01-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
 | 2009005075OK.pdf | 491.87 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Triclabendazole (TCBZ) has been the drug of choice to treat liver fluke infections in livestock for > 20 years, due to its high activity against both adult and juvenile flukes. More recently, it has been used successfully to treat human cases of fascioliasis. Resistance to TCBZ first appeared in the field in Australia in the mid-1990s. Since then, resistance has been reported from a number of countries throughout Europe: Ireland, Scotland, Wales, Spain and The Netherlands. The heavy reliance on a single drug puts treatment strategies for fascioliasis at risk. Should resistance develop further, the prospect is an alarming one. This review will present an overview of progress in understanding the mechanism of resistance to TCBZ, examining possible changes in the target molecule, in drug influx/efflux mechanisms and in the metabolism of TCBZ by the fluke. The review will also consider ways to deal with resistance, covering drug-oriented options such as: the use of alternative drugs, drug combinations and the search for new compounds. © 2007 Elsevier Inc. All rights reserved.
Please use this identifier to cite or link to this item: